TBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Telesis Bio's Cost of Goods Sold for the three months ended in Dec. 2023 was $2.23 Mil. Its Revenue for the three months ended in Dec. 2023 was $6.98 Mil.
Telesis Bio's COGS to Revenue for the three months ended in Dec. 2023 was 0.32.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Telesis Bio's Gross Margin % for the three months ended in Dec. 2023 was 68.07%.
The historical data trend for Telesis Bio's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telesis Bio Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
COGS-to-Revenue | - | 0.45 | 0.61 | 0.43 | 0.38 |
Telesis Bio Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
COGS-to-Revenue | Get a 7-Day Free Trial | 0.32 | 0.44 | 0.34 | 0.46 | 0.32 |
Telesis Bio's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 10.559 | / | 27.509 | |
= | 0.38 |
Telesis Bio's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 2.228 | / | 6.977 | |
= | 0.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telesis Bio (NAS:TBIO) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Telesis Bio's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 2.228 / 6.977 | |
= | 68.07 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Telesis Bio's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Gregory J. Herrema | director | 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134 |
Marijn E Dekkers | 10 percent owner | GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210 |
Novalis Lifesciences Investments Ii Gp, Llc | 10 percent owner | 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842 |
Novalis Lifesciences Investments Ii, L.p. | 10 percent owner | 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842 |
Broadoak Fund Iv, Llc | 10 percent owner | 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814 |
William Snider | director, 10 percent owner | 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814 |
Paul M Meister | director, 10 percent owner | 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862 |
Rob Cutler | officer: Chief Legal Officer | C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Daniel Glenn Gibson | officer: Chief Technology Officer | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Todd Robert Nelson | director, 10 percent owner, officer: President & CEO | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Eric Eugene Esser | officer: Chief Operating Officer | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121 |
Annette Tumolo | director | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Northpond Ventures Gp, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
Northpond Ventures Gp Ii, Llc | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814 |
Northpond Ventures Ii, Lp | 10 percent owner | 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814 |
From GuruFocus
By sperokesalga sperokesalga • 03-21-2023
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 08-10-2023
By Marketwired • 11-07-2023
By Marketwired • 09-28-2023
By sperokesalga sperokesalga • 02-27-2023
By sperokesalga sperokesalga • 06-08-2023
By sperokesalga sperokesalga • 04-27-2023
By GlobeNewswire GlobeNewswire • 05-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.